<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02707926</url>
  </required_header>
  <id_info>
    <org_study_id>1601M83126</org_study_id>
    <nct_id>NCT02707926</nct_id>
  </id_info>
  <brief_title>The Lymphoid Tissue Pharmacology of Antiretroviral Drugs</brief_title>
  <official_title>The Lymphoid Tissue Pharmacology of Antiretroviral Drugs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis:&#xD;
&#xD;
      Antiretroviral drugs (ARVs) with enhanced LT penetration characteristics in vitro and in&#xD;
      macaques will translate into an ARV regimen with increased LN and GALT concentrations and a&#xD;
      faster decay and more potent suppression of HIV replication in LT in HIV-infected persons.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
        1. Determine lymph nodes (LN) and gut-associated lymphoid tissue (GALT) pharmacokinetics&#xD;
           (PK) in HIV-infected persons on an antiretroviral drug (ARV) regimen.&#xD;
&#xD;
        2. Determine virological responses of antiretroviral therapy in plasma, peripheral blood&#xD;
           mononuclear cells (PBMCs) and lymphoid tissue (LT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center study of 18 ARV naïve, HIV infected persons to assess impact of an&#xD;
      ARV regimen on lymph node (LN) and (GALT) virus reservoirs.&#xD;
&#xD;
      All participants will give informed consent. At baseline, plasma and PBMCs will be obtained&#xD;
      and all subjects will have an incisional biopsy of an inguinal LN and pinch biopsy of ileum&#xD;
      and rectum via colonoscopy. The selected LT-enhanced ARV regimen will be initiated.&#xD;
      Participants will return to the clinic at weeks 2 and 4 and then monthly for safety&#xD;
      evaluations, CD4 T cell counts, plasma HIV-RNA and ARV drug concentrations in plasma and&#xD;
      PBMCs. An intensive PK study will be performed at week 2. At months 3 and 6, the inguinal LN&#xD;
      biopsy and pinch biopsies of ileum and rectum will be repeated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2022</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Lymph node (LN) tissue penetration ratio.</measure>
    <time_frame>6 months</time_frame>
    <description>Ratio of antiretroviral drug concentration in lymph node (LN) to peripheral blood mononuclear cells (PBMCs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lymph node (LN) residual viremia.</measure>
    <time_frame>6 months</time_frame>
    <description>Quantification of residual viremia in lymph node (LN) at 6 months of therapy as measured by digital droplet polymerase chain reaction (PCR), which can quantify as low as 50 copies/million cells.</description>
  </primary_outcome>
  <enrollment type="Anticipated">18</enrollment>
  <condition>HIV Infection</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-HIV Agents</intervention_name>
    <description>Therapy to treat HIV infection</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, urine, lymph node biopsy, colonoscopy biopsy of ileum and rectum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Eighteen (18) antiretroviral drug (ARV)-naive, HIV-infected persons who are going to&#xD;
        initiate ARV therapy will be recruited at the University of Minnesota. Study entry is open&#xD;
        to adults regardless of race or ethnic background. While there will be every effort to seek&#xD;
        out and include minority participants from both genders, the patient population is expected&#xD;
        to be no different than that of the HIV infected population in Minnesota.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Antiretroviral drug (ARV)-naive, HIV-infected individuals&#xD;
&#xD;
          2. Aged 18 years or over&#xD;
&#xD;
          3. Agree to initiating ARV therapy&#xD;
&#xD;
          4. BMI ≤ 30&#xD;
&#xD;
          5. Inguinal lymph node(s) identifiable by ultrasound at enrollment&#xD;
&#xD;
          6. Screening plasma HIV RNA &gt; 40,000 copies/mL&#xD;
&#xD;
          7. Screening CD4 count &gt; 200 cells/mm3&#xD;
&#xD;
          8. Women of child bearing potential must agree to use effective contraception while on&#xD;
             the study.&#xD;
&#xD;
          9. Screening viral isolates demonstrate genotype sensitivity to chosen antiretroviral&#xD;
             therapy (ART) regimen.&#xD;
&#xD;
         10. Able to provide voluntary written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous ARV therapy&#xD;
&#xD;
          2. Contraindications to ARV regimen (e.g., comorbid conditions or drug interactions), or&#xD;
             study procedures as determined by the principal investigator.&#xD;
&#xD;
          3. Planning or current pregnancy or breastfeeding&#xD;
&#xD;
          4. History and/or presence of any clinically significant disease or disorder, such as&#xD;
             cardiovascular, pulmonary, renal, hepatic, neurological, gastrointestinal and&#xD;
             psychiatric/mental disease/disorder, which, in the opinion of the enrolling physician,&#xD;
             may put the participant at risk because of participation in the study, influence the&#xD;
             results of the study, or affect the participant's ability to participate in the study.&#xD;
&#xD;
          5. Inability to comply with study procedures per enrolling physician discretion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tim Schacker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Courtney V Fletcher, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ann Thorkelson, MN, RN</last_name>
    <phone>612-625-7472</phone>
    <email>segu0017@umn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tim Schacker, MD</last_name>
    <phone>612-624-9955</phone>
    <email>schac008@umn.edu</email>
  </overall_contact_backup>
  <reference>
    <citation>Lorenzo-Redondo R, Fryer HR, Bedford T, Kim EY, Archer J, Pond SLK, Chung YS, Penugonda S, Chipman J, Fletcher CV, Schacker TW, Malim MH, Rambaut A, Haase AT, McLean AR, Wolinsky SM. Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature. 2016 Feb 4;530(7588):51-56. doi: 10.1038/nature16933. Epub 2016 Jan 27.</citation>
    <PMID>26814962</PMID>
  </reference>
  <reference>
    <citation>Fletcher CV, Staskus K, Wietgrefe SW, Rothenberger M, Reilly C, Chipman JG, Beilman GJ, Khoruts A, Thorkelson A, Schmidt TE, Anderson J, Perkey K, Stevenson M, Perelson AS, Douek DC, Haase AT, Schacker TW. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2307-12. doi: 10.1073/pnas.1318249111. Epub 2014 Jan 27.</citation>
    <PMID>24469825</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 3, 2016</study_first_submitted>
  <study_first_submitted_qc>March 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2016</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska</investigator_affiliation>
    <investigator_full_name>Courtney Fletcher</investigator_full_name>
    <investigator_title>Professor and Director, Antiviral Pharmacology Laboratory</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-HIV Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The results of this trial will be of interest to the HIV research and medical communities. We expect to submit the data from the main analysis within 6 months of completing the work. We will publish the results in a major scientific journal and present the results at a major scientific meeting (e.g., CROI). Subsequent analyses will be presented at national and international HIV meetings. Data generated under this project, and any intellectual property, will be administered in accordance with NIH policies, including the NIH Data Sharing Policy the NIH Public Access Policy.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

